Companies / Industrials
VRSK
Verisk Analytics
Research & Consulting Services
Research & Consulting ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health77
Growth48
Profitability100
Cash generation100
Balance sheet46
Dilution control90
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)5.3%Revenue growth (FY)6.6%Revenue CAGR (3y)7.2%Gross margin69.9%Operating margin43.7%Net margin29.6%Free cash flow margin38.8%R&D / revenue1.3%Stock comp / revenue1.8%Net debt / operating cash flow1.81xCurrent ratio1.20Diluted share count change-1.9%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $2.5B | $2.5B | $2.7B | $2.9B | $3.1B |
| Gross profit | $1.6B | $1.7B | $1.8B | $2.0B | $2.1B |
| Operating income | $911M | $1.4B | $1.1B | $1.3B | $1.3B |
| Net income | $666M | $954M | $615M | $958M | $908M |
| Operating cash flow | $1.2B | $1.1B | $1.1B | $1.1B | $1.4B |
| Capital expenditure | $268M | $275M | $230M | $224M | $244M |
| Free cash flow | $887M | $784M | $831M | $920M | $1.2B |
| R&D | $47M | $43M | $37M | $35M | $41M |
| Stock-based comp | $56M | $56M | $54M | $48M | $54M |
| Buybacks | $475M | $1.7B | $2.8B | $1.0B | $624M |
| Dividends | $188M | $195M | $197M | $221M | $251M |
| Cash | $112M | $112M | $303M | $291M | $2.2B |
| Total debt | $3.3B | $3.7B | $2.9B | $3.1B | $4.8B |
| Equity | $2.8B | $1.7B | $310M | $100M | $309M |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.